Moreover, downregulation of lncRNA cancer susceptibility candidate 2 (CASC2) was reported in various tumors including glioma, endometrial, and RCC which is correlated with tumor malignant features and worse prognosis (Ghafouri-Fard et al., 2020[12]). This evidence concerns the gene CASC2 and renal cell carcinoma.